Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Two-year ocular and developmental outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity

David K. Wallace,Amra Hercinovic,Sharon F. Freedman,Eric R. Crouch,Amit R. Bhatt,M. Elizabeth Hartnett,Michael B. Yang,David L. Rogers,Amy K. Hutchinson,William V. Good,Michael X. Repka,Raymond T. Kraker,Susan A. Cotter,Jonathan M. Holmes

Journal of American Association for Pediatric Ophthalmology and Strabismus（2022）

Cited 0|Views19
No score
Abstract
Previously, we reported intravitreous bevacizumab doses as low as 0.004 mg (<1% of BEAT-ROP dose) were effective in treating type 1 ROP. We now report two-year outcomes after low-dose and very low-dose bevacizumab.
More
Translated text
Key words
retinopathy,bevacizumab,prematurity,two-year
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined